After obtaining his degree in Biochemistry and Applied Clinical Biochemistry from UMIST in 2001, Andrew completed a PhD in Molecular Parasitology from the University of Manchester, studying the folate biosynthetic pathway of the malaria parasite Plasmodium falciparum. In 2006 he joined the Sinden lab at Imperial College, London, to study the sexual stages of Plasmodium, with an emphasis on developing transmission-blocking interventions (TBIs) to target the parasite within the mosquito host, inhibiting or preventing the onward transmission of malaria. He is currently a Principal Investigator in the DoLS, and his main interests focus on the identification of novel anti-malarial transmission blocking vaccine targets, vaccine delivery, the development of assays to examine TBI efficacy, and assessing the practical impact of introducing TBIs on populations of mosquitoes and vertebrate in both the laboratory and the field.
et al., 2019, Male-specific protein disulphide isomerase function is essential for plasmodium transmission and a vulnerable target for intervention, Scientific Reports, Vol:9, ISSN:2045-2322
et al., 2019, The effects of dyslipidaemia and cholesterol modulation on erythrocyte susceptibility to malaria parasite infection, Malaria Journal, Vol:18, ISSN:1475-2875
et al., 2019, Immune responses to gametocyte antigens in a malaria endemic population-the African falciparum context: a systematic review and meta-analysis, Frontiers in Immunology, Vol:10, ISSN:1664-3224, Pages:1-14
et al., 2018, Characterization of a protozoan Phosducin-like protein-3 (PhLP-3) reveals conserved redox activity, Plos One, Vol:13, ISSN:1932-6203, Pages:1-21
et al., 2019, DEMONSTRATION OF A BLOOD-STAGE CONTROLLED HUMAN MALARIA INFECTION MODEL FOR PLASMODIUM VIVAX VACCINE EFFICACY TESTING, 68th Annual Meeting of the American-Society-for-Tropical-Medicine-and-Hygiene (ASTMH), AMER SOC TROP MED & HYGIENE, Pages:133-134, ISSN:0002-9637